Circulating Tumor DNA Clinical Trial
Official title:
Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study
For patients with stage III colon cancers, radical resection of primary tumor followed by adjuvant chemotherapy is currently the standard treatment. Adjuvant chemotherapy with 5-fluorouracil and oxaliplatin based regimen has been proved effective to improve recurrence-free survival and overall survival. Approximately half of patients with stage III colon cancers can be cured by surgery alone, while a substantial number of patients still experience recurrence, even with standard adjuvant chemotherapy. In recent years, circulating tumor DNA (ctDNA) has been detected in the cell-free component of peripheral blood samples in advanced colorectal cancers and many other solid tumors. Several previous studies have suggested that in patients with stage I-III colorectal cancer, postoperative ctDNA was an valuable biomarker to predict minimal residual disease (MRD) after radical resection, thus redefining patients risk outcome groups and guiding postoperative treatment. In addition, recent studies based on serial postoperative ctDNA detection showed that serial ctDNA analyses revealed disease recurrence up to 5-16.5 months ahead of radiological imaging. Here, based on the role of ctDNA in predicting MRD, we conducted an open, prospective, randomized controlled phase II cohort study to explore if ctDNA can as a biomarker to guide personalized surveillance strategy after surgery.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
| Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
| Recruiting |
NCT04555369 -
The Value of ctDNA on Chemotherapy Efficacy for mCRC
|
N/A | |
| Not yet recruiting |
NCT03688035 -
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
|
||
| Not yet recruiting |
NCT05027828 -
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
|
||
| Recruiting |
NCT03737539 -
Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
|
||
| Not yet recruiting |
NCT04511559 -
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
|
||
| Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02620527 -
Concordance Between ctDNA Assay and FoundationOne
|
||
| Recruiting |
NCT05529615 -
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
|
N/A | |
| Recruiting |
NCT05601505 -
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
| Recruiting |
NCT04966663 -
Using ctDNA to Determine Therapies for Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05801276 -
ctDNA Methylation for Detecting Ovarian Cancer
|
||
| Recruiting |
NCT05801263 -
ctDNA Methylation for Epithelial Ovarian Cancer
|
||
| Active, not recruiting |
NCT04276337 -
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
|
||
| Recruiting |
NCT05969938 -
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
|
||
| Completed |
NCT04456972 -
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
|
N/A | |
| Completed |
NCT03750175 -
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
|
||
| Recruiting |
NCT04457297 -
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
|
Phase 3 |